Abstract:Objective: To summarize the clinical features and genetic mutation characteristics of Chinese children with KCNQ2-related epilepsy. Methods: A cohort of children with genetically caused epilepsy was evaluated at Linyi People's Hospital from January 2017 to December 2023. After next-generation sequencing and pathogenicity analysis, we summarized the medical records and genetic testing data of the children who had KCNQ2 gene mutations. Results: We identified 23 KCNQ2 gene mutations. 73.9% (n = 17) of the mutation sites were located in S5-S6 segments and the C-terminal region. In addition to the common phenotypes, 2 new phenotypes were identified: infantile convulsion with paroxysmal choreoathetosis (ICCA) and febrile seizure plus (FS+). Of all the cases with abnormal video-electro-encephalography, three cases with self-limited familial infantile epilepsy (SeLNE) exhibited a small number of multifocal discharges. Of the patients who have taken a particular antiepileptic drug, the statistics on the number of patients who have responded to the drug are as follows: oxcarbazepine (8/9, 88.9%), levetiracetam (5/7, 71.4%), phenobarbital (9/16, 56.3%), and topiramate (2/5, 40.0%). However, the efficacy of phenobarbital varied widely in treating SeLNE and KCNQ2-DEE. At the final follow-up, 1 case with SeLNE had a transient developmental regression and 7 cases with KCNQ2-DEE had mild to severe developmental backwardness. Significance: Although clinically rare, we report 10 new KCNQ2 mutations and two new phenotypes: ICCA and FS+. This further expands genetic and phenotypic spectrum of KCNQ2-related epilepsy. The gene mutation sites are mostly located in S5-S6 segments and the C-terminal region, and the former is usually associated with KCNQ2-DEE. Sodium channel blockers (including oxcarbazepine and topiramate) and levetiracetam should be prioritized over phenobarbital for KCNQ2-DEE. Some cases with KCNQ2-related epilepsy may have transient developmental regression during periods of frequent seizures. Early treatment and early seizure control may be beneficial for willing outcomes in children with KCNQ2-DEE. Plain language summary: This article reports 23 cases of children with KCNQ2-related epilepsy, including 10 new mutation sites and 2 new phenotypes. It further expands the genetic and phenotypic spectrum of KCNQ2-related epilepsy. In addition, the article summarizes the gene mutation characteristics and clinical manifestations of children with KCNQ2-related epilepsy, with the expectation of providing a certain theoretical basis for the diagnosis and treatment of such patients.

Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy

Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy

Investigation of novel de novo KCNC2 variants causing severe developmental and early-onset epileptic encephalopathy

Epilepsy phenotype and response to KCNQ openers in mice harboring the Kcnq2 R207W voltage-sensor mutation

High-throughput Evaluation of Epilepsy-associated KCNQ2 Variants Reveals Functional and Pharmacological Heterogeneity

Novel KCNQ2 Missense Variant Expands the Genotype Spectrum of DEE7.

A structurally precise mechanism links an epilepsy-associated KCNC2 potassium channel mutation to interneuron dysfunction

Targeting Heterozygous Dominant Negative Variant of KCNA2 Using Gapmer ASO for the Treatment of Drug-Resistant Epilepsy

Clinical and genetic analysis of 23 Chinese children with epilepsy associated with KCNQ2 gene mutations

The Epilepsy of Infancy With Migrating Focal Seizures: Identification of de novo Mutations of the KCNT2 Gene That Exert Inhibitory Effects on the Corresponding Heteromeric KNa1.1/KNa1.2 Potassium Channel

Plural molecular and cellular mechanisms of pore domain KCNQ2 encephalopathy

Distinct epilepsy phenotypes and response to drugs in KCNA1 gain‐ and loss‐of function variants

Clinical Phenotypes of Developmental and Epileptic Encephalopathy-Related Recurrent KCNH5 Missense Variant P.r327h in Chinese Children

Improved classification and pathogenicity assessment by comprehensive functional studies in a large data set of KCNQ2 variants

Loss-of-function variants in the KCNQ5 gene are implicated in genetic generalized epilepsies

Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions

CONSTITUTIVE OPENING OF THE Kv7.2 PORE ACTIVATION GATE CAUSES KCNQ2-DEVELOPMENTAL ENCEPHALOPATHY

Electrophysiological Features: the Next Precise Step for SCN2A Developmental Epileptic Encephalopathy

Targeting heterozygous dominant negative variant of KCNA2 using Gapmer antisense oligonucleotides (ASO) for the treatment of drug-resistant epilepsy

KCNQ2 ‐DEE: developmental or epileptic encephalopathy?

Lipophilic compounds restore wt function of neurodevelopmental-associated KCNQ3 mutations